Acute myocardial infarction and thyroid function: New pathophysiological and therapeutic perspectives

Annals of Medicine

Volumn 44, Issue 8, 2012, Pages 745-757

  Pingitore, Alessandro ^a   Chen, Yuefeng ^b   Gerdes, Anthony Martin ^b   Iervasi, Giorgio ^a  

^a FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Acute myocardial infarction; Cellular survival mechanisms; Left ventricular remodeling; Myocardial protection; Thyroid hormone

Indexed keywords

3,5 DIIODOTHYROPROPIONIC ACID; FIBRINOLYTIC AGENT; LIOTHYRONINE; LIOTHYRONINE SODIUM; LIOTIR; PLACEBO; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROXINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIOGENESIS; APOPTOSIS; CELL REGENERATION; CORONARY STENT; DISEASE COURSE; GENE EXPRESSION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE REMODELING; HORMONE SUBSTITUTION; HUMAN; MITOCHONDRION; MOLECULAR THERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THYROID FUNCTION; THYROID GLAND; THYROID HORMONE BLOOD LEVEL; TRANSLUMINAL CORONARY ANGIOPLASTY;

CELL SURVIVAL; HEART; HUMANS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RECEPTORS, THYROID HORMONE; REGENERATION; THYROXINE; TRIIODOTHYRONINE; VENTRICULAR REMODELING;

EID: 84857909406     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.573501     Document Type: Review

References (105)

1. Lloyed-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
2. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J. 2008;29:2909-45.
3. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43-51.
4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
5. Araskiewicz A, Grajek S, Lesiak M, Prech M, Pyda M, Janus M, et al. Effect of impaired myocardial reperfusion on left remodelling in patients with anterior wall acute myocardial infarction treated with primary coronary intervention. Am J Cardiol. 2006;98:725-8.
6. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (writing Committee to Develop Performance Measures for ST-elevation and Non STelevation Myocardial Infarction). J Am Coll Cardiol. 2008; 52:2046-99.
7. Dixon JA, Spinale FG. Pathophysiology of myocardial injury and remodelling: implications for molecular imaging. J Nucl Med. 2010;51:102S-6S.
8. Pfeffer MA. Left ventricular remodelling after acute myocardial infarction. Ann Rev Med. 1995;46:455-66.
9. Gerdes AM, Kellerman SE, Moore JA, Muffly KE, Clark LC, Reaves PY, et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation . 1992;86:426-30.
10. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left venticular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long term prognosis. Circulation. 2002; 106: 2351-7.
11. St John Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, et al. Cardiovascular death and left ventricular remodelling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997;96: 3294-9.
12. Wong SP, French JK, Lydon AM, Manda SO, Gao W, Ashton NG, et al. Relation of left ventricular sphericity to 10-year survival after acute myocardial infarction. Am J Cardiol. 2004;94:1270-5.
13. Depre C, Vatner SF. Cardioprotection in stunned and hibernating myocardium. Heart Fail Rev. 2007;12:307-17.
14. Kloner RA, Rezkalla SH. Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res. 2006;70:297-307.
15. Kitakaze M. How to mediate cardioprotection in ischemic hearts-accumulated evidence of basic research should translate to clinical medicine. Cardiovasc Drugs Ther. 2010; 24:217-23.
16. Yan L, Vatner DE, Kim SJ, Ge H, Masurekar M, Massover WH, et al. Autophagy in chronically ischemic myocardium. Proc Natl Acad Sci USA. 2005;102:13807-12.
17. Mai W, Janier MF, Allioli N, Quignodon L, Chuzel T, Flamant F, et al. Thyroid hormone receptor is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci USA. 2004;101:10332-7.
18. Pantos C, Mourouzis I, Cokkinos DV. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail Rev . 2011;16:79-96.
19. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D. Thyroid hormone and' cardiac metamorphosis' : potential therapeutic implications. Pharmacol Ther . 2008; 118:277-94.
20. Ojamaa K, Kenessey A, Shenoy R, Klein I. Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat. Am J Physiol Endocrinol Metab. 2000;279:E1319-24.
21. Chen YF, Redetzke RA, Said S, Beyer AJ, Gerdes AM. Changes in left ventricular function and remodeling after myocardial infarction in hypothyroid rats. Am J Physiol Heart Circ Physiol . 2010;298:H259-62.
22. Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation . 2005;112:3122-30.
23. Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Kokkinos AD, et al. Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg . 2007;32:333-9.
24. Lee YK, Ng KM, Chan YC, Lai WH, Au KW, Ho CY, et al. Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway. Mol Endocrinol. 2010;24:1728-36.
25. C ampbell SE, Gerdes AM. Regional changes in myocyte size during the reversal of thyroid-induced cardiac hypertrophy. J Mol Cell Cardiol. 1988;20:379-87.
26. Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH, Holder MS, et al. Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure. Am J Physiol Heart Circ Physiol. 2005;288:H2118-22.
27. Olivares EL, Marassi MP, Fortunato RS, da Silva AC, Costa-e-Sousa RH, Araújo IG, et al. Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. Endocrinology. 2007;148:4786-92.
28. Pantos C, Mourouzis I, Galanopoulos G, Gavra M, Perimenis P, Spanou D, et al. Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res. 2010;42:718-24.
29. Pol CJ, Muller A, Zuidwijk MJ, van Deel ED, Kaptein E, Saba A, et al. Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition. Endocrinology. 2011;152:669-79.
30. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med. 1994;331:847-53.
31. Pantos C, Mourouzis I, Saranteas T, Paizis I, Xinaris C, Malliopoulou V, et al. Thyroid hormone receptors alpha1 and beta1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion. Basic Res Cardiol. 2005;100:422-32.
32. Pantos C, Mourouzis I, Xinaris C, Kokkinos AD, Markakis K, Dimopoulos A, et al. Time-dependent changes in the expression of thyroid hormone receptor alpha 1 in the myocardium after acute myocardial infarction: possible implications in cardiac remodelling. Eur J Endocrinol. 2007;156:415-24.
33. Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, et al. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol. 2008;44: 180-7.
34. Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV. Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol. 2008;103:308-18.
35. Gay R, Gustafson TA, Goldman S, Morkin E. Effects of L-thyroxine in rats with chronic heart failure after myocardial infarction. Am J Physiol. 1987;253(2 Pt 2):H341-6.
36. Gay RG, Graham S, Aguirre M, Goldman S, Morkin E. Effects of 10-to 12-day treatment with L-thyroxine in rats with myocardial infarction. Am J Physiol. 1988;255(4 Pt 2): H801-6.
37. Pantos C, Mourouzis I, Tsagoulis N, Markakis K, Galanopoulos G, Roukounakis N, et al. Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J Physiol Pharmacol. 2009;60:49-56.
38. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail. 2009;2:243-52.
39. Kalofoutis C, Mourouzis I, Galanopoulos G, Dimopoulos A, Perimenis P, Spanou D, et al. Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. Mol Cell Biochem. 2010;345:161-9.
40. Kuzman JA, Gerdes AM, Kobayashi S, Liang Q. Thyroid hormone activates Akt and prevents serum starvationinduced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2005;39:841-4.
41. Pantos C, Mourouzis I, Saranteas T, Clavé G, Ligeret H, Noack-Fraissignes P, et al. Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Res Cardiol. 2009; 104:69-77.
42. Eckle T, K öh ler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation. 2008 118:166-75.
43. Makino A, Suarez J, Wang H, Belke DD, Scott BT, Dillmann WH. Thyroid hormone receptor-beta is associated with coronary angiogenesis during pathological cardiac hypertrophy. Endocrinology. 2009;150:2008-15.
44. Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC1alpha. Cardiovasc Res. 2008;79:208-17.
45. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial transition pore opening during myocardial reperfusion: a target for cardioprotection. Cardiovasc Res. 2004;61:372-85.
46. Chen YF, Bathia S, Redetzke RA, Coburn T, Gerdes AM. Thyroid hormone improves left ventricular myocyte remodeling after myocardial infarction in rats. J Card Fail. 2009; 15:S73.
47. Chilian WM, Wangler RD, Peters KG, Tomanek RJ, Marcus ML. Thyroxine-induced left ventricular hypertrophy in the rat. Anatomical and physiological evidence for angiogenesis. Circ Res. 1985;57:591-8.
48. Tomanek RJ, Connell PM, Butters CA, Torry RJ. Compensated coronary microvascular growth in senescent rats with thyroxine-induced cardiac hypertrophy. Am J Physiol. 1995;268(1 Pt 2):H419-25.
49. Tomanek RJ, Busch TL. Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat Rec. 1998;251:44-9.
50. Breisch EA, White FC, Hammond HK, Flynn S, Bloor CM. Myocardial characteristics of thyroxine stimulated hypertrophy. A structural and functional study. Basic Res Cardiol. 1989;84:345-58.
51. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res. 2004;94:1500-6.
52. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005;146:2864-71.
53. Kazmierczak P, Polak A, Mussur M. Influence of preischemic short-term triiodothyronine administration on hemodynamic function and metabolism of reperfused isolated rat heart. Med Sci Monit. 2004;10:BR381-7.
54. Tse J, Gandhi A, Yan L, He YQ, Weiss HR. Effects of triiodothyronine pretreatment on beta-adrenergic responses in stunned cardiac myocytes. J Cardiothorac Vasc Anesth. 2003;17:486-90.
55. Novitzky D, Matthews N, Shawley D, Cooper DK, Zuhdi N. Triiodothyronine in the recovery of stunned myocardium in dogs. Ann Thorac Surg. 1991;51:10-6; discussion 16-7.
56. Yokoyama Y, Novitzky D, Deal MT, Snow TR. Facilitated recovery of cardiac performance by triiodothyronine following a transient ischemic insult. Cardiology. 1992;81:34-45.
57. Holland FW 2nd, Brown PS Jr, Clark RE. Acute severe postischemic myocardial depression reversed by triiodothyronine. Ann Thorac Surg. 1992;54:301-5.
58. Wechsler AS, Kadletz M, Ding M, Abd-Elfattah A, Dyke C. Effects of triiodothyronine on stunned myocardium. J Card Surg. 1993;8(2 Suppl):338-41.
59. Dyke CM, Ding M, Abd-Elfattah AS, Loesser K, Dignan RJ, Wechsler AS, et al. Effects of triiodothyronine supplementation after myocardial ischemia. Ann Thorac Surg. 1993;56: 215-22.
60. Klemperer JD, Zelano J, Helm RE, Berman K, Ojamaa K, Klein I, et al. Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia. J Thorac Cardiovasc Surg. 1995;109:457-65.
61. Hsu RB, Huang TS, Chen YS, Chu SH. Effect of triiodothyronine administration in experimental myocardial injury. J Endocrinol Invest. 1995;18:702-9.
62. Liu Q, Clanachan AS, Lopaschuk GD. Acute effects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts. Am J Physiol. 1998;275 (3 Pt 1):E392-9.
63. Novitzky D, Human PA, Cooper DK. Effect of triiodothyronine (T3) on myocardial high energy phosphates and lactate after ischemia and cardiopulmonary bypass. An experimental study in baboons. J Thorac Cardiovasc Surg. 1988;96:600-7.
64. Novitzky D, Human PA, Cooper DK. Inotropic effect of triiodothyronine following myocardial ischemia and cardiopulmonary bypass: an experimental study in pigs. Ann Thorac Surg. 1988;45:50-5.
65. Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, et al. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem. 2003; 242:173-80.
66. Pantos C, Malliopoulou V, Mourouzis I, Karamanoli E, Moraitis P, Tzeis S, et al. Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. Eur J Pharmacol. 2003;478:53-60.
67. Halapas A, Lembessis P, Mourouzis I, Pantos C, Cokkinos DV, Sourla A, et al. Experimental hyperthyroidism increases expression of parathyroid hormone-related peptide and type-1 parathyroid hormone receptor in rat ventricular myocardium of the Langendorff ischaemiareperfusion model. Exp Physiol. 2008;93:237-46.
68. Venditti P, Agnisola C, Di Meo S. Effect of ischemiareperfusion on heart mitochondria from hyperthyroid rats. Cardiovasc Res. 2002;56:76-85.
69. Masullo P, Venditti P, Agnisola C, Di Meo S. Role of nitric oxide in the reperfusion induced injury in hyperthyroid rat hearts. Free Radic Res. 2000;32:411-21.
70. Pavon N, Aranda A, Garcia N, Hernandez-Esquivel L, Chavez E. In hyperthyroid rats octylguanidine protects the heart from reperfusion damage. Endocrine. 2009;35:158-65.
71. Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid downregulation of thyroid hormones in acute myocardial infarction. Is it cardioprotective in patients with angina? Arch Int Med. 2002;162:1388-94.
72. Kimur T, Kotajima N, Kanda T, Kuwabara A, Fukumura Y, Kobayashi I. Correlation of circulating interleukin-10 with thyroid hormone in acute myocardial infarction. Res Commun Mol Pharmacol. 2001;110:63-58.
73. Ceremuzynski L, Czerwosz L, Chamiec T, Bartoszewicz Z, Herbaczynska-Cedro K. Low serum triiodotrhyronine in acute myocardial infarction indicates major heart injury. Kardiol Pol. 2004;60:468-80.
74. Wiersinga WM, Lie KI, Touber JL. Thyroid hormones in acute myocardial infarction. Clin Endocrinol. 1981;14:367-74.
75. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999; 84:151-64.
76. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107:708-13.
77. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007;167:1526-32.
78. Pingitore A, Landi P, Taddei MC, Ripoli A, L'Abbate A, Iervasi G, et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118: 132-6.
79. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al.; Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304:1365-74.
80. Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A, Witteman JCM. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med. 2000;132:70-8.
81. Yun KH, Jeong MH, Lee EM, Lee J, Rhee SJ, Yoo NJ, et al. Relationship of thyroid stimulating hormone with coronary athrosclerosis in angina patients. Int J Cardiol. 2007;122:56-60.
82. Coceani M, Iervasi G, Pingitore A, Carpeggiani C, L' A bbate A. Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications. Clin Cardiol . 2009;32:380-5.
83. Friberg L, Drvota V, Bjelak AH, Eggertsen G, Ahnve S. Association between increased levels of reverse T3 and mortality after acute myocardial infarction. Am J Med. 2001; 111: 699-703.
84. Kocher A. Ueber morbus Basedowi. Mitt Grenzgeb Med Chir. 1901;1:1-13.
85. Greenfield WS. Autopsy findings in a 58 year old woman with myxoedema. Published as an appendix to Ord WM. Med Chir Trans. 1878;61:57.
86. Somerville W, Levine SA. Angina pectoris and thyrotoxicosis. Br Heart J. 1950;12:245-57.
87. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA. 1972;220:996-1008.
88. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and peripheral production of 3,5,3 '-triiodothyronine in humans by multicompartmental analysis. Am J Physiol. 1990;258:E715-26.
89. Young WF Jr, Gorman CA, Jiang NS, Machacek D, Hay ID. L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect. Clin Pharmacol Ther. 1984;36:781-7.
90. Jones RJ, Cohen L. Sodium dextro-thyrxine in coronary disease and hypercholesteremia. Circulation. 1961;24;164-70.
91. Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, et al. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation. 2006;114:I245-50.
92. Portman MA, Slee A, Olson AK, Cohen G, Karl T, Tong E, et al. TRICC Investigators. Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebocontrolled randomized trial: age analysis. Circulation. 2010;122:S224-33.
93. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93:1351-8.
94. Mebis L, van den Berghe G. The hypothalamus-pituitarythyroid axis in critical illness. Neth J Med . 2009;67: 332-40.
95. Liu Y, Redetzke RA, Said S, Pottala JV, de Escobar GM, Gerdes AM. Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am J Physiol Heart Circ Physiol . 2008;294:H2137-43.
96. Peeters RP, van der Geyten S, Wouters PJ, DarrasVM, van Toor H, Kaptein E, et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab. 2005;90:6498-507.
97. De K, Ghosh G, Datta M, Konar A, Bandyopadhyay J, Bandyopadhyay D, et al. Analysis of differentially expressed genes in hyperthyroid-induced hypertrophied heart by cDNA microarray. J Endocrinol. 2004;182:303-14.
98. Goldman S, McCarren M, Morkin E, Ladenson PW, Edson R, Warren S, et al. DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation. 2009;119:3093-100.
99. Schultz RL, Swallow JC, Waters RP, Kuzman JA, Redetzke RA, Said S, et al. Effects of excessive longterm exercise on cardiac function and myocyte remodeling in hypertensive heart failure rats. Hypertension. 2007;50: 410-6.
100. Tribulova N, Knezl V, Shainberg A, Seki S, Soukup T. Thyroid hormones and cardiac arrhythmias. Vascul Pharmacol . 2010;52:102-12.
101. Betsuyaku T, Kanno S, Lerner DL, Schuessler RB, Saffitz JE, Yamada KA. Spontaneous and inducible ventricular arrhythmias after myocardial infarction in mice. Cardiovasc Pathol. 2004;13:156-64.
102. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation. 1993;87;1435-41.
103. Manoach M, Tribulova N, Vogelezang D, Thomas S, Podzuweit T. Transient ventricular fibrillation and myosin heavy chain isoform profile. J Cell Mol Med . 2007;11:171-4.
104. Cini G, Carpi A, Mechanick J, Cini L, Camici M, Galetta F, et al. Thyroid hormones and the cardiovascular system: Pathophysiology and interventions. Biomed Pharmacother. 2009;63:742-53.
105. Maseri A. Forewords. Iervasi G, Pingitore A, editors. Thyroid and heart failure: from pathophysiology to clinics. Milan and New York: Springer; 2009.